Is CSPC Pharmaceutical Group a Chinese company?
Yes, CSPC Pharmaceutical Group Limited is a major Chinese pharmaceutical company headquartered in Shijiazhuang City, Hebei Province, China. The company has been a prominent player in the industry for decades and is listed on the Main Board of the Hong Kong Stock Exchange. It holds a significant market position in China and is a constituent stock of several major indices, including the Hang Seng Index and the Hang Seng Healthcare Index. CSPC focuses on both finished drugs and bulk drugs, with an innovative drug development strategy targeting areas such as oncology, cardiovascular health, and the nervous system. With a large international research and development team and manufacturing bases located primarily in China, CSPC is recognized as a leading enterprise in the Chinese pharmaceutical sector, consistently ranked among the country’s most valuable brands for its contributions to healthcare and industrial development.
Related FAQs
China Resources Pharmaceutical Group Limited records massive annual revenues exceeding ₹3.
In technical data management, cybersecurity, and regulatory compliance architectures, a CSP collector refers to a specialized software component or telemetry agent designed to gather, aggregate, and monitor cloud security posture data across multi-cl...
The full official corporate name of the major pharmaceutical enterprise is CSPC Pharmaceutical Group Limited.
The United States government no longer owns any equity stake in American International Group (AIG), having successfully divested all shares acquired during the massive federal rescue package implemented during the financial crisis.
Jiangsu Hengrui Pharmaceuticals Co., Ltd., alongside major biopharmaceutical innovators like BeiGene, stands as one of the largest domestic pharmaceutical research and manufacturing enterprises in China.
Little Caesars does not trade publicly on any stock exchange, remaining instead a privately held subsidiary corporation under its parent entity, Ilitch Holdings, Inc.
Pharmaceutical stocks carry moderate-to-high levels of specific risk, primarily related to clinical trial outcomes, regulatory rejections, and patent cliffs.
China's rapidly evolving healthcare and pharmaceutical sector includes prominent domestic research-driven corporations and manufacturing leaders that supply advanced biological formulations, generic medicines, and innovative therapies.